EP0000649B1 - 5-substituted-1,2-dihydro-3h-pyrrolo(1,2-a)pyrrole-1-carbonitriles and process for their conversion to the corresponding 1-carboxylic acids - Google Patents

5-substituted-1,2-dihydro-3h-pyrrolo(1,2-a)pyrrole-1-carbonitriles and process for their conversion to the corresponding 1-carboxylic acids Download PDF

Info

Publication number
EP0000649B1
EP0000649B1 EP78300174A EP78300174A EP0000649B1 EP 0000649 B1 EP0000649 B1 EP 0000649B1 EP 78300174 A EP78300174 A EP 78300174A EP 78300174 A EP78300174 A EP 78300174A EP 0000649 B1 EP0000649 B1 EP 0000649B1
Authority
EP
European Patent Office
Prior art keywords
pyrrole
pyrrolo
dihydro
nitrile
thenoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP78300174A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0000649A1 (en
Inventor
Albert R. Van Horn
Pasquale G. Gallegra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25225403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0000649(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of EP0000649A1 publication Critical patent/EP0000649A1/en
Application granted granted Critical
Publication of EP0000649B1 publication Critical patent/EP0000649B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to 5-substituted-1,2-dihydro-3H-pyrrolo [1,2-a]-pyrrole derivatives useful as intermediates in the preparation of pharmaceutically active compounds, and to such preparative processes.
  • the present invention provides novel 5-substituted-1,2-dihydro-3H-pyrrolo [1,2-a]-pyrrole-1-nitriles of the formula :
  • the compounds of Formula (II) can, in accordance with the process hereof, be converted hydrolyticallyto the corresponding 5-substituted-1,2-dihydro-3H-pyrrolo-[1,2-a] pyrrole-1-carboxylic acids of the formula : wherein Y is defined as above.
  • the product compounds hereof of Formula (I) are useful as antiinflammatory agents, analgetic agents, and as smooth muscle relaxants. They can be used both prophylactically and therapeutically. See for example Netherlands Specifications Nos. 7707651, 7707652 and 7803378.
  • the present invention provides an alternative route for the preparation of the compounds of Formula I.
  • the new process hereof that is, the hydrolysis conversion of the compounds of Formula (II) to the compounds of Formula (I) can be carried out under a variety of acidic or basic conditions, generally those conditions employed by those skilled in the art for the conversion of nitriles to carboxylic acids.
  • hydrolysis conversion is carried out under acidic conditions it is generally preferred that it be done with a strong mineral acid, e.g., phosphoric acid, sulfuric acid, hydrochloric acid, hydrobromic acid. and the like, in the presence of water, with or without the presence of an organic acid, e.g., acetic acid, formic acid, propionic acid, and the like. If desired other organic solvents miscible with the mineral acid (and the water and the organic acid, if the latter is used) can be used.
  • a strong mineral acid e.g., phosphoric acid, sulfuric acid, hydrochloric acid, hydrobromic acid. and the like
  • an organic acid e.g., acetic acid, formic acid, propionic acid, and the like.
  • other organic solvents miscible with the mineral acid (and the water and the organic acid, if the latter is used) can be used.
  • Suitable organic solvents are methanol, ethanol, ethylene glycol, dimethylsulfoxide, dioxane, tetrahydrofuran, ethylene glycol dimethyl ether (glyme), diethylene glycol dimethyl ether (diglyme), and the like.
  • the reaction is preferably carried out under an inert atmosphere, e.g., nitrogen, argon, and the like, with nitrogen being the most preferred.
  • the reaction times and temperatures are not critical and depend, as will be apparent to those skilled in the art, on the reactants (and other ingredients of the reaction mixture) employed. Thus, the reaction time can be from about one minute to about 10 hours with about five minutes to about three hours being preferred ; and the reaction temperature from about 60 °C to about 200 °C, with about 80 °C to about 120 °C being preferred.
  • hydrolysis conversion is carried out under basic conditions, it is generally preferred that it be done with a strong base, preferably a mineral base, e.g., potassium hydroxide, sodium hydroxide, lithium hydroxide, and the like, in the presence of water.
  • a strong base preferably a mineral base, e.g., potassium hydroxide, sodium hydroxide, lithium hydroxide, and the like
  • water miscible organic solvents e.g., 2-methoxyethanol, methanol, ethanol, ethylene glycol, dimethylsulfoxide, and the like are used to facilitate solution of the reactants.
  • the reaction is preferably carried out under an inert atmosphere, e.g., nitrogen, argon, and the like, with nitrogen being the most preferred.
  • reaction times and temperatures are not critical and depend, as will be apparent to those skilled in the art, on the reactants (and other ingredients of the reaction mixture) employed.
  • reaction time can be from about 5 minutes to about 2 hours, with about 30 minutes to about 1 hour being preferred ; and the reaction temperature from about 60 °C to reflux temperature with about 70 °C to reflux temperature being preferred.
  • Isolation, separation, and purification of the desired compound of Formula (I) from the reaction mixture containing it can be effected by any suitable separation or purification procedure, such as, for example, extractions, filtration, evaporation, distillation, crystallization, thin-layer chromatography, or column chromatography, high pressure liquid chromatography, and the like, or a combination of these procedures. Illustrations of suitable isolation, separation and purification procedures can be had by reference to the Examples (and Preparations) hereinbelow. However, other isolation, separation and purification procedures, could of course, also be used.
  • temperatures are room or ambient temperature (about 20 °C to about 30 °C).
  • the temperature is permitted to drop to room temperature and the reaction mixture is agitated to room temperature for 15 hours, followed by the addition of 16 ml of 25 % aqueous sodium hydroxide solution, agitation for 5 minutes, and the addition of 19 ml of methylene chloride and 20 ml of water.
  • the organic layer is separated and the aqueous layer is extracted with 19 ml of methylene chloride.
  • the organic portions are combined and washed with a mixture of 11 ml of saturated aqueous sodium chloride solution and 8 ml of water.
  • reaction mixture is then added to a hot (about 90 °C) solution of 12.6 g of sodium cyanide in 27 ml of water, the addition being at such a rate, while at the same time distilling the solvent off, that the internal reaction flask temperature is kept at about 90 °-95 °C.
  • the addition is complete, the mixture is brought to reflux and heated under reflux for 15 minutes.
  • the mixture is cooled to 25 °C, followed by the addition of 40 ml of water and 60 ml of methylene chloride.
  • the organic layer is separated, washed wifh 30 ml of a mixture of 50 : 50 saturated aqueous sodium chloride : water, the water layer is extracted twice with 30 ml of methylene chloride, and the combined organic layers are dried over anhydrous sodium sulfate and the solvent removed under vacuum to yield 21 g of a brown oil which upon purification on a silica gel chromatography column (using 50 : 50-ethyl acetate : hexane as solvent) yielded 13 g of 1-hydroxyethylpyrrole-2-acetonitrile having the following analysis :
  • the thus-obtained mixture is heated to 77 °C for one hour, cooled to 25°C, and 15 ml of methylene chloride is added thereto.
  • the organic salts are filtered off and washed with methylene chloride.
  • the solvent is removed from the filtrate under vacuum, leaving a residue which is taken up in a mixture of 30 ml of dilute aqueous sodium chloride solution.
  • the volume is then adjusted to about 2 ml by the addition of ethyl acetate, followed by cooling to 0°C and filtration to yield 0.2 g (50 %) 5-(2-thenoyl)-1,2-dihydro-3H-pyrrolo [1,2-a] pyrrole-1-carboxylic acid having a melting point of 147°-148 °C.
  • the melting point remained the same following a second crystallization from ethyl acetate and high pressure liquid chromatography indicated a purity of 79.8 %.
  • 0.45 g of the crude product is taken up in 5 ml of hot ethyl acetate, cooled to 0 °C agitated for five minutes, and following filtration, washing with 2 ml of a 2 : 1 ethyl acetate-hexane mixture and vacuum drying at 45 °C there is obtained 0.32 g (71 % w/w) of 5-(2-thenoyl)-1,2-dihydro-3H-pyrrolo [1,2-a] pyrrole-1-carboxylic acid having a melting point of 157 °C-159 °C. Additional quantities of the product can be obtained by standard crystallization work-up procedures.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP78300174A 1977-07-25 1978-07-20 5-substituted-1,2-dihydro-3h-pyrrolo(1,2-a)pyrrole-1-carbonitriles and process for their conversion to the corresponding 1-carboxylic acids Expired EP0000649B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81837777A 1977-07-25 1977-07-25
US818377 1977-07-25

Publications (2)

Publication Number Publication Date
EP0000649A1 EP0000649A1 (en) 1979-02-07
EP0000649B1 true EP0000649B1 (en) 1981-03-25

Family

ID=25225403

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78300174A Expired EP0000649B1 (en) 1977-07-25 1978-07-20 5-substituted-1,2-dihydro-3h-pyrrolo(1,2-a)pyrrole-1-carbonitriles and process for their conversion to the corresponding 1-carboxylic acids

Country Status (27)

Country Link
US (1) US4140698A (enrdf_load_stackoverflow)
EP (1) EP0000649B1 (enrdf_load_stackoverflow)
JP (1) JPS5424889A (enrdf_load_stackoverflow)
AT (1) AT364843B (enrdf_load_stackoverflow)
AU (1) AU515352B2 (enrdf_load_stackoverflow)
CA (1) CA1111431A (enrdf_load_stackoverflow)
CS (1) CS201015B2 (enrdf_load_stackoverflow)
DD (1) DD137229A5 (enrdf_load_stackoverflow)
DE (1) DE2860560D1 (enrdf_load_stackoverflow)
DK (1) DK146720C (enrdf_load_stackoverflow)
ES (1) ES472002A1 (enrdf_load_stackoverflow)
FI (1) FI64597C (enrdf_load_stackoverflow)
GR (1) GR63733B (enrdf_load_stackoverflow)
HK (1) HK17186A (enrdf_load_stackoverflow)
HU (1) HU178354B (enrdf_load_stackoverflow)
IE (1) IE47138B1 (enrdf_load_stackoverflow)
IL (1) IL55181A (enrdf_load_stackoverflow)
IT (1) IT1160443B (enrdf_load_stackoverflow)
MY (1) MY8800142A (enrdf_load_stackoverflow)
NO (2) NO166863C (enrdf_load_stackoverflow)
NZ (1) NZ187924A (enrdf_load_stackoverflow)
PL (1) PL111419B1 (enrdf_load_stackoverflow)
PT (1) PT68328A (enrdf_load_stackoverflow)
SG (1) SG31884G (enrdf_load_stackoverflow)
SU (1) SU1138029A3 (enrdf_load_stackoverflow)
YU (1) YU40717B (enrdf_load_stackoverflow)
ZA (1) ZA784216B (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4232038A (en) * 1979-08-31 1980-11-04 Syntex (U.S.A.) Inc. 5-Alkylsulfinylbenzoyl- and 5-alkylsulfonylbenzoyl-1,2-dihydro-3H-pyrrolo[1,]pyrrole-1-carboxylic acids
ATE7694T1 (de) * 1980-02-14 1984-06-15 Grigg, Ronald Ernest Derivate von 2-methyl-5-thiazolmethylamin und carboxamid.
US4344943A (en) * 1980-06-09 1982-08-17 Syntex (U.S.A.) Inc. 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo[1,2-a]-pyrrole-1-carboxylic acids and derivatives thereof
US4353829A (en) * 1980-11-21 1982-10-12 Syntex (U.S.A.) Inc. Process for 5-aroylation of 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic esters
US4397862A (en) * 1981-10-13 1983-08-09 Syntex (U.S.A.) Inc. Gastrointestinal sparing thioester drugs
WO1983001382A1 (en) * 1981-10-13 1983-04-28 Mroszczak, Edward Gastrointestinal sparing thioester pro-drugs
US4457941A (en) * 1982-03-22 1984-07-03 Syntex (U.S.A.) Inc. Use of pyrrolo-pyrrole in treating microvascular diseases associated with diabetes
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
EP0117675B1 (en) * 1983-02-19 1986-07-23 Beecham Group Plc Benzofuran and benzothiophene-carboxylic-acid derivatives
US4874871A (en) * 1987-03-25 1989-10-17 Syntex (U.S.A.) Inc. Process for preparing (+)-2,3-Dihydro-1H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid and related compounds
JP2649168B2 (ja) * 1988-02-25 1997-09-03 久光製薬株式会社 新規な５，６−ジフェニル−１，２−ジヒドロ−３Ｈ−ピロロ［１，２−ａ］ピロール−１−カルボン酸誘導体
AU7255394A (en) * 1993-07-08 1995-02-06 Cygnus Therapeutic Systems Monolithic matrix transdermal delivery system
US5621115A (en) * 1996-02-21 1997-04-15 Ohmeda Pharmaceutical Products Division Inc. Methods for preparing 5-aroyl-1,2-dihydro-3H-pyrrolo-[1,2-A]pyrrole-1-carboxylic acids
US6191285B1 (en) 1997-07-03 2001-02-20 Abbott Laboratories Process for the preparation of ketorolac tromethamine
ES2259475T3 (es) * 1998-07-10 2006-10-01 Mallinckrodt Inc. Sintesis de compuestos utiles en la fabricacion de ketorolac.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087539A (en) * 1976-07-14 1978-05-02 Syntex (U.S.A.) Inc. 5-(2-Furoyl)-, 5-(2-thenoyl)-, 5-(3-furoyl)- and 5-(3-thenoyl)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
JPS539788A (en) * 1976-07-14 1978-01-28 Syntex Inc 55aloyll1*22dihydroo3hh pyroro *1*22a* pyroll11 carboxylic acid derivative
JPS539789A (en) * 1976-07-14 1978-01-28 Syntex Inc Production of 55*22floyl** * 55*22thenoyl** * 55*33 floyl** and 55*33thenoyl** 1*22dihydroo3hhpyroro * 1*22a*pyrolee11carboxylic acid derivative
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4097579A (en) * 1977-03-31 1978-06-27 Syntex (U.S.A.) Inc. 5-(2-Pyrroyl)-1,2-dihydro-3H-pyrrolo 1,2-a!pyrrole-1-carboxylic acid derivatives and process for the production thereof

Also Published As

Publication number Publication date
IT1160443B (it) 1987-03-11
ZA784216B (en) 1980-02-27
HU178354B (en) 1982-04-28
SU1138029A3 (ru) 1985-01-30
AU3826978A (en) 1980-01-31
DD137229A5 (de) 1979-08-22
IE781473L (en) 1979-01-25
DK146720C (da) 1984-08-20
PT68328A (en) 1978-08-01
CS201015B2 (en) 1980-10-31
PL208576A1 (pl) 1979-05-07
DE2860560D1 (en) 1981-04-16
MY8800142A (en) 1988-12-31
ATA528978A (de) 1981-04-15
CA1111431A (en) 1981-10-27
YU174178A (en) 1983-01-21
NO851935L (no) 1979-01-26
IL55181A (en) 1981-12-31
PL111419B1 (en) 1980-08-30
NO166863C (no) 1991-09-11
IE47138B1 (en) 1983-12-28
NO155244C (no) 1987-03-04
YU40717B (en) 1986-04-30
FI64597B (fi) 1983-08-31
GR63733B (en) 1979-12-04
DK325078A (da) 1979-01-26
US4140698A (en) 1979-02-20
IL55181A0 (en) 1978-09-29
FI64597C (fi) 1983-12-12
AT364843B (de) 1981-11-25
NO166863B (no) 1991-06-03
JPS5424889A (en) 1979-02-24
EP0000649A1 (en) 1979-02-07
DK146720B (da) 1983-12-12
FI782307A7 (fi) 1979-01-26
AU515352B2 (en) 1981-04-02
IT7868765A0 (it) 1978-07-24
NZ187924A (en) 1980-03-05
HK17186A (en) 1986-03-21
ES472002A1 (es) 1984-07-16
NO155244B (no) 1986-11-24
NO782545L (no) 1979-01-26
SG31884G (en) 1985-09-13
JPS6337793B2 (enrdf_load_stackoverflow) 1988-07-27

Similar Documents

Publication Publication Date Title
EP0000649B1 (en) 5-substituted-1,2-dihydro-3h-pyrrolo(1,2-a)pyrrole-1-carbonitriles and process for their conversion to the corresponding 1-carboxylic acids
EP0428437B1 (fr) Dérivés du 1,2-benzisoxazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
EP0001534B1 (fr) Nouveaux dérivés du pyrrole, leur procédé de préparation et leurs applications en thérapeutique
CH619463A5 (enrdf_load_stackoverflow)
JPS59130863A (ja) ５―ビニル―２―ピロリジノンの製法
AU625664B2 (en) 3,4-Dehydropiperidine derivatives having psychotropic activity
EP0139584B1 (fr) Dérivés d'imidazoline, leur préparation et leur application en thérapeutique
EP0008249A2 (fr) Dérivés de fluorènes et fluoranthènes, leur procédé de préparation et leur application en thérapeutique
NL8004081A (nl) Werkwijze voor het bereiden van een farmaceutisch preparaat met analgetische en anti-inflammatoire werking, onder toepassing daarvan verkregen gevormd preparaat en werkwijze voor het bereiden van een ester van 4-(2-carboxylfenylamino-7-trifluormethylchinoline of 4-(2-carboxylfenylamino)-8-trifluormethylchinoline.
RU2024506C1 (ru) Производные пирролидина и способ их получения
GB2204037A (en) N-substituted 4-hydroxypyridine-3-carboxamides
EP0000453B1 (fr) Procédé de préparation de dérivés de la thiénopyridine
JP3101012B2 (ja) ２−アリール−５−（トリフルオロメチル）ピロール化合物の製造方法
CA2010529A1 (fr) Derives de la 1-arylsulfonyl 2-piperidinone, leur procede et les intermediaires de preparation, leur application comme medicaments et les compositions les renfermant
WO1998049149A1 (en) Preparation of mibefradil i
EP1023283B1 (en) Synthesis of 3-carbomethoxy-4,5-dimethylthiophene
KR810001173B1 (ko) 신규의 대응 니트릴로부터 5-치환-1,2-디하이드로-3H-피롤로[1,2-a]-피롤-1-카르복실 산을 제조하는 방법
JPS6258358B2 (enrdf_load_stackoverflow)
CH624939A5 (enrdf_load_stackoverflow)
CA1085412A (fr) Acides thienothienylcarbonylphenylalcanoiques, leurs derives, leur preparation et les compositions qui les contiennent
FR2694287A1 (fr) Nouvelles cycloalkylalkylamines ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique.
JP2002533334A (ja) 抗ヒスタミン活性を有する三環式化合物を調製するためのプロセス
WO1990015060A1 (en) 4,5,6,11-TETRAHYDROBENZO[6,7]CYCLOOCTA[1,2-b]THIOPHEN-6,11-IMINES AND 6,11-DIHYDROBENZO[6,7]CYCLOOCTA[1,2-b]THIOPHEN-6,11-IMINES
CA1127652A (en) Process for producing dibenzothiepin propionamide derivatives
CA2010713A1 (fr) Derives de la 1-arylsulfonyl pyrrolidin-2-thione ou de la 1-arylsulfonyl piperidin-2-thione, leur procede de preparation, leur application comme medicaments et les compositions les renfermant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

REF Corresponds to:

Ref document number: 2860560

Country of ref document: DE

Date of ref document: 19810416

EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 78300174.6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19970617

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19970620

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19970625

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19970711

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19970729

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19970808

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19970911

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19971014

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 980720 *SYNTEX (U.S.A.) INC.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980719

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980720

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980721

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 19980719

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 19980720

EUG Se: european patent has lapsed

Ref document number: 78300174.6

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT